GlobeNewsWire
08 Jul 2026, 13:45 UTC · 18w ago
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
Impact · against what's priced in
MAIA Biotechnology reports high efficacy in a resistant NSCLC population, significantly exceeding standard-of-care chemotherapy disease control rates. This constitutes a positive clinical catalyst for the company's lead candidate, ateganosine.
- MAIA+0.70
No priced-in read yet





